ForTra is announcing a call for proposals to fund consulting costs for the preparation and support of orientation (´kick-off´) and scientific advice meetings with regulatory authorities for projects for which a clinical trial is planned.
The interplay of adverse environmental factors and predisposing genetic alterations can lead to the development of inflammatory bowel disease such as ulcerative colitis. Gut bacteria play an important role in this context and endogenous anti-microbial peptides contribute to regulating their diversity. In this project, we will produce a modified anti-microbial peptide for subsequent clinical testing.
Further information here.
More than 1 in 10 adults worldwide is affected by chronic kidney disease (CKD), making it one of the leading causes of death globally. While a wide range of conditions can lead to chronic kidney failure, they all converge on a common pathological process: fibrosis, the progressive scarring of kidney tissue. Despite its central role in disease progression, effective anti-fibrotic therapies for broad use in CKD patients are still lacking.
Precision-RNA is pioneering an innovative platform to bring personalized RNA-based treatments into clinics - starting with severe, currently untreatable brain diseases. Using programmable molecules called antisense oligonucleotides (ASOs), the platform can be tailored to each patient’s unique genetic mutation, yet remains scalable by applying a shared biological mechanism across many rare diseases. This innovative approach has already led to two individualized treatments for the rare neurological disease Ataxia-Telangiectasia, now in clinical use.
Researchers at the University Hospital of Cologne have identified promising, fully human antibodies that specifically neutralize a central virulence factor of the multidrug-resistant bacterium Pseudomonas aeruginosa. This bacterium causes severe infections, particularly in immunocompromised and ventilated patients. The antibodies are directed against the type III secretion system of the pathogen and show significantly higher efficacy in preclinical models than previously available approaches.
Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis is the most common autoimmune encephalitis. Current broadly immunosuppressive treatments are often limited by side effects, necessitating the exploration of more effective and autoantibody-specific alternatives.
